Literature DB >> 17237138

Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function.

Thomas Jank1, Torsten Giesemann, Klaus Aktories.   

Abstract

Clostridium difficile causes pseudomembranous colitis and is responsible for many cases of nosocomial antibiotic-associated diarrhea. Major virulence factors of C. difficile are the glucosylating exotoxins A and B. Both toxins enter target cells in a pH- dependent manner from endosomes by forming pores. They translocate the N-terminal catalytic domains into the cytosol of host cells and inactivate Rho guanosine triphosphatases by glucosylation. The crystal structure of the catalytic domain of toxin B was solved in a complex with uridine diphosphate, glucose, and manganese ion, exhibiting a folding of type A family glycosyltransferases. Crystallization of fragments of the C-terminus of toxin A, which is characterized by polypeptide repeats, revealed a solenoid-like structure often found in bacterial cell surface proteins. These studies, which provide new insights into structure, uptake, and function of the family of clostridial glucosylating toxins, are reviewed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237138     DOI: 10.1093/glycob/cwm004

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  69 in total

1.  Molecular characteristics of Clostridium perfringens TpeL toxin and consequences of mono-O-GlcNAcylation of Ras in living cells.

Authors:  Gregor Guttenberg; Sven Hornei; Thomas Jank; Carsten Schwan; Wei Lü; Oliver Einsle; Panagiotis Papatheodorou; Klaus Aktories
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

2.  Structural determinants of Clostridium difficile toxin A glucosyltransferase activity.

Authors:  Rory N Pruitt; Nicole M Chumbler; Stacey A Rutherford; Melissa A Farrow; David B Friedman; Ben Spiller; D Borden Lacy
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

3.  Transcriptional profiling of Clostridium difficile and Caco-2 cells during infection.

Authors:  Tavan Janvilisri; Joy Scaria; Yung-Fu Chang
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

4.  Clostridium perfringens TpeL glycosylates the Rac and Ras subfamily proteins.

Authors:  Masahiro Nagahama; Akiko Ohkubo; Masataka Oda; Keiko Kobayashi; Katsuhiko Amimoto; Kazuaki Miyamoto; Jun Sakurai
Journal:  Infect Immun       Date:  2010-11-22       Impact factor: 3.441

Review 5.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

6.  Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.

Authors:  Patima Permpoonpattana; Huynh A Hong; Jutarop Phetcharaburanin; Jen-Min Huang; Jenny Cook; Neil F Fairweather; Simon M Cutting
Journal:  Infect Immun       Date:  2011-04-11       Impact factor: 3.441

7.  The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

Authors:  Justyna Bien; Vindhya Palagani; Przemyslaw Bozko
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

Review 8.  Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen.

Authors:  Milena M Awad; Priscilla A Johanesen; Glen P Carter; Edward Rose; Dena Lyras
Journal:  Gut Microbes       Date:  2014

9.  Protective efficacy induced by recombinant Clostridium difficile toxin fragments.

Authors:  Rosanna Leuzzi; Janice Spencer; Anthony Buckley; Cecilia Brettoni; Manuele Martinelli; Lorenza Tulli; Sara Marchi; Enrico Luzzi; June Irvine; Denise Candlish; Daniele Veggi; Werner Pansegrau; Luigi Fiaschi; Silvana Savino; Erwin Swennen; Osman Cakici; Ernesto Oviedo-Orta; Monica Giraldi; Barbara Baudner; Nunzia D'Urzo; Domenico Maione; Marco Soriani; Rino Rappuoli; Mariagrazia Pizza; Gillian R Douce; Maria Scarselli
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441

10.  Recombinant Mucin-Type Fusion Proteins with a Galα1,3Gal Substitution as Clostridium difficile Toxin A Inhibitors.

Authors:  Reeja Maria Cherian; Chunsheng Jin; Jining Liu; Niclas G Karlsson; Jan Holgersson
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.